Have a feature idea you'd love to see implemented?
Let us know!
MIRM Mirum Pharmaceuticals Inc
Price (delayed)
$43.48
Market cap
$2.09B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.08
Enterprise value
$2.18B
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
Highlights
The revenue has soared by 112% YoY and by 16% from the previous quarter
The company's gross profit has surged by 89% YoY and by 17% QoQ
The quick ratio has declined by 36% year-on-year
Mirum Pharmaceuticals's equity has decreased by 14% YoY
Key stats
What are the main financial stats of MIRM
Market
Valuations
Earnings
Shares outstanding
48M
Market cap
$2.09B
Enterprise value
$2.18B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.94
Price to sales (P/S)
6.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.11
Revenue
$307.03M
EBIT
-$83.69M
EBITDA
-$59.49M
Free cash flow
-$2.2M
Per share
Balance sheet
Liquidity
EPS
-$2.08
Free cash flow per share
-$0.05
Book value per share
$4.86
Revenue per share
$6.43
TBVPS
$8.62
Total assets
$667.89M
Total liabilities
$435.87M
Debt
$317.65M
Equity
$232.02M
Working capital
$270.88M
Debt to equity
1.37
Current ratio
3.34
Quick ratio
3.05
Net debt/EBITDA
-1.58
Margins
Efficiency
Dividend
EBITDA margin
-19.4%
Gross margin
72.7%
Net margin
-32.5%
Operating margin
-31.3%
Return on assets
-15.2%
Return on equity
-42.3%
Return on invested capital
-24.2%
Return on capital employed
-15.2%
Return on sales
-27.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIRM stock price
How has the Mirum Pharmaceuticals stock price performed over time
Intraday
-0.48%
1 week
-6.01%
1 month
10.5%
1 year
35.88%
YTD
47.29%
QTD
11.49%
Financial performance
How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$307.03M
Gross profit
$223.15M
Operating income
-$95.97M
Net income
-$99.81M
Gross margin
72.7%
Net margin
-32.5%
The revenue has soared by 112% YoY and by 16% from the previous quarter
The company's gross profit has surged by 89% YoY and by 17% QoQ
The company's net margin has surged by 71% YoY and by 21% QoQ
The operating margin has soared by 59% YoY and by 24% from the previous quarter
Growth
What is Mirum Pharmaceuticals's growth rate over time
Valuation
What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.94
P/S
6.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.11
The EPS has soared by 52% YoY and by 11% from the previous quarter
MIRM's price to book (P/B) is 60% higher than its 5-year quarterly average of 5.6 and 40% higher than its last 4 quarters average of 6.4
Mirum Pharmaceuticals's equity has decreased by 14% YoY
The revenue has soared by 112% YoY and by 16% from the previous quarter
MIRM's price to sales (P/S) is 13% higher than its last 4 quarters average of 6.0
Efficiency
How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 73% YoY and by 22% from the previous quarter
Mirum Pharmaceuticals's return on assets has surged by 59% YoY and by 9% QoQ
The ROE has soared by 59% YoY and by 4.9% QoQ
The ROIC has soared by 54% YoY and by 15% from the previous quarter
Dividends
What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIRM.
Financial health
How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 53% higher than its total liabilities
The quick ratio has declined by 36% year-on-year
The company's current ratio fell by 36% YoY
The company's debt is 37% higher than its equity
The debt to equity has grown by 20% YoY
Mirum Pharmaceuticals's equity has decreased by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.